» Articles » PMID: 35911285

Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept

Overview
Journal Cureus
Date 2022 Aug 1
PMID 35911285
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system with incredibly intricate etiopathogenesis involving numerous genetic, epigenetic, and environmental risk factors. Major environmental risk factors include ultraviolet (UV) radiation, vitamin D, Epstein-Barr virus (EBV) infection, smoking, and high body mass index (BMI). Vitamin D, in particular, can be viewed as one piece of this puzzle, with various tabs and pockets, occupying a sequential site. In this article, we have briefly discussed the neuroimmunology of MS and the role of vitamin D in regulating immune responses. Various observational studies and clinical trials were reviewed and discussed according to stages of disease activity and course of the disease. The data reviewed in this article implied that serum vitamin D levels greatly influence the risk of developing MS and disease activity. Long-term follow-up studies indicated that low serum vitamin D levels correlate with worse disability outcomes. Since clinical trials did not provide significant evidence, the role of vitamin D in controlling disease activity remains unresolved. Larger clinical trials are needed to support the findings of observational studies and provide significant evidence in favour of vitamin D.

Citing Articles

Role of innate immune cells in multiple sclerosis.

Prado C, Herrada A, Hevia D, Goiry L, Escobedo N Front Immunol. 2025; 16:1540263.

PMID: 40034690 PMC: 11872933. DOI: 10.3389/fimmu.2025.1540263.


The Power of Vitamin D: Is the Future in Precision Nutrition through Personalized Supplementation Plans?.

Mavar M, Soric T, Bagaric E, Saric A, Matek Saric M Nutrients. 2024; 16(8).

PMID: 38674867 PMC: 11054101. DOI: 10.3390/nu16081176.


Impact of calcitriol and PGD-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination.

Mwema A, Gratpain V, Ucakar B, Vanvarenberg K, Perdaens O, van Pesch V Drug Deliv Transl Res. 2024; 14(11):3128-3146.

PMID: 38366115 DOI: 10.1007/s13346-024-01535-8.


1,25(OH)D3 Differently Modulates the Secretory Activity of IFN-DC and IL4-DC: A Study in Cells from Healthy Donors and MS Patients.

Sanseverino I, Rinaldi A, Purificato C, Cortese A, Millefiorini E, Gauzzi M Int J Mol Sci. 2023; 24(7).

PMID: 37047690 PMC: 10094841. DOI: 10.3390/ijms24076717.


Radiological Benefits of Vitamin D Status and Supplementation in Patients with MS-A Two-Year Prospective Observational Cohort Study.

Galus W, Chmiela T, Walawska-Hrycek A, Krzystanek E Nutrients. 2023; 15(6).

PMID: 36986195 PMC: 10052720. DOI: 10.3390/nu15061465.


References
1.
Lassmann H . Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013; 333(1-2):1-4. DOI: 10.1016/j.jns.2013.05.010. View

2.
Kampman M, Brustad M . Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology. 2008; 30(3):140-6. DOI: 10.1159/000122330. View

3.
Atashi Shirazi H, Rasouli J, Ciric B, Rostami A, Zhang G . 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015; 98(2):240-5. PMC: 4400846. DOI: 10.1016/j.yexmp.2015.02.004. View

4.
Smolders J, Torkildsen O, Camu W, Holmoy T . An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs. 2019; 33(12):1187-1199. PMC: 6890630. DOI: 10.1007/s40263-019-00674-8. View

5.
Scazzone C, Agnello L, Bivona G, Lo Sasso B, Ciaccio M . Vitamin D and Genetic Susceptibility to Multiple Sclerosis. Biochem Genet. 2020; 59(1):1-30. DOI: 10.1007/s10528-020-10010-1. View